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RLate Gadolinium Enhancement
and Higher Risk of Arrhythmias
Fibrosis or Increased
Ventricular Wall Stress?
Current criteria indicating implantable cardioverter-defibrillator
(ICD) therapy for primary prevention of sudden cardiac death are
poor, and non–evidence-based ICD implantations are more likely
to have worse outcomes. Therefore, Iles et al. (1) examined late
gadolinium enhancement (LGE) by using cardiac magnetic reso-
nance imaging to predict appropriate device therapy in patients
with ischemic and nonischemic cardiomyopathy. The study relies
on the assumptions that myocardial fibrosis is the substrate of
LGE and that fibrosis is associated with arrhythmias.
Well-documented links between fibrosis and LGE exist in
patients who have experienced myocardial infarction in whom
nonviable cardiomyocytes are replaced by collagen. This contigu-
ous subendocardial or transmural area can be detected by a bright
LGE pattern. Histological changes are very different in patients
with dilative cardiomyopathies. Histopathological studies have
shown that the myocardial remodeling can be associated with an
increased collagen volume fraction, and in transmural left ventric-
ular sections, the extent of fibrosis increased from epicardium to
endocardium and from the right to the left side of the septum (2).
LGE occurs as midwall (septal) streak (1) or is irregularly diffuse.
Thus, in dilative cardiomyopathies, causes beyond fibrosis should
be taken into account for LGE.
In the study by Iles et al. (1), all patients with ischemic
cardiomyopathy exhibited LGE, and the ICD discharge rate was
14%, whereas it was 29% in patients with nonischemic cardiomy-
opathy and LGE. Also, based on the absence of differences in left
ventricular ejection fraction and end-diastolic volume index, it was
concluded that fibrosis predicts appropriate ICD therapy. How-
ever, it remains to be assessed whether indeed fibrosis or an
increased wall stress was responsible for LGE and ICD therapy.
Using echocardiography-based ventricular mass and geometry
data, we suggest calculating wall stress and examining the conten-
tion that patients with ICD therapy exhibit increased wall stress.
In accordance with a role of wall stress for LGE, our recent
study on 300 patients with dilative cardiomyopathy showed that a
rise in wall stress (3) was associated with LGE (4). Most likely,
higher wall stress is associated with an increased capillary leakage,
and thus favors contrast medium emission into the interstitial
space. Also, its venous clearance can be prolonged by an impaired
redistribution. The link of LGE with arrhythmias would follow
from experimental studies in which myocardial stretch and neuro-
humoral reactions predispose patients to arrhythmias involving, for
example, stretch-activated cation channels.
The proposed subanalysis also could clarify whether LGE per se
is an independent prognostic predictor or a dependent surrogatemarker. Thus, in a study of 141 patients with dilated cardiomy-
opathy, the prognostic value of LGE regarding survival was found
only by univariate, but not by multivariate, analysis (5). Increased
wall stress thus could be the underlying mechanism of a worse
prognosis and should be evaluated also as indicator for ICD
therapy.
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Reply
Drs. Alter and Rupp propose that late gadolinium enhancement
(LGE) in nonischemic cardiomyopathy may be the result of
increased myocardial wall stress with resultant increased capillary
permeability and reduced venous return.
In our study (1), patients without LGE did not experience
implantable cardioverter-defibrillator discharges, suggesting that
this group may be at lower risk for malignant ventricular arrhyth-
mia. LGE previously was demonstrated to correlate well with
ischemic regional fibrosis (2) and also in limited human studies in
nonischemic pathological conditions (3). Therefore, we postulated
the likely mechanism for implantable cardioverter-defibrillator
discharges in advanced cardiomyopathy to be the presence of
regional scar acting as an arrhythmogenic substrate. However,
regardless of the mechanism, a lack of LGE was associated with a
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ing supported by other studies (4,5). As wall stress also is increased
in advanced cardiomyopathy, the association between LGE and
wall stress referred to by the authors is not surprising, because
LGE also is a feature of advanced cardiomyopathy (4,5).
One would expect that if increased wall stress is the underlying
mechanism of myocardial contrast enhancement, it is likely to be
diffuse rather than the focal process observed with LGE. Diffuse
contrast enhancement cannot be detected with the technique of
LGE, because this method requires the presence of apparently
normal adjacent myocardium without contrast enhancement.
However, because shortened post-contrast myocardial T1 times
have been shown to correlate with histological fibrosis (6) in
patients with cardiomyopathy, wall stress as the underlying mech-
anism of contrast enhancement seems unlikely. Interestingly,
recent research in hypertensive patients revealed an absence of
LGE despite increased wall stress compared with controls (7).
To determine conclusively that wall stress contributes to the
presence of LGE in nonischemic cardiomyopathy independently
of regional fibrosis would require contemporaneous measurement
of LGE and wall stress coupled with histological examination of
areas of myocardium in which LGE is present. To our knowledge,
this has not been performed, and given the lack of invasive pressure
measurement along with the unavailability of histological samples,
such analysis is not possible from our study population.
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Dynamic Left Ventricular
Outflow Tract Obstruction
and Acute Heart Failure in
Tako-Tsubo Cardiomyopathy
Given the relative paucity of data regarding tako-tsubo cardiomy-
opathy (TC) and the risk of heart failure, Madhavan et al. (1) are
to be commended for their work recently published in the Journal.
However, we wish to raise one issue not mentioned in their
paper. It is recognized that TC can be complicated by reversible
systolic anterior motion (SAM) of the mitral valve (MV) with
dynamic left ventricular outflow tract obstruction (LVOTO) (2).
This can be associated with significant mitral regurgitation (MR).
The pathophysiological basis of this complication remains un-
known. Two studies, both including more than 100 patients, each
reported an incidence of SAM and LVOTO in more than 10% of
TC cases (3,4). Thus, dynamic LVOTO is certainly not a rare
phenomenon in association with TC.
Hypotension may develop in patients with TC first due to left
ventricular systolic dysfunction, second due to significant MR
secondary to SAM of the MV, third due to dynamic LVOTO, or
fourth a combination of these factors (5). Alternatively, hypoten-
sive patients presenting with chest pain and ischemic electrocar-
diographic changes may, of course, have cardiogenic shock due to
acute coronary syndrome. It is clinically important to differentiate
the cause of hypotension in such patients because the immediate
management varies depending on the underlying etiology.
In patients with acute coronary syndrome, intra-aortic balloon
pump (IABP) counterpulsation improves coronary perfusion (dur-
ing diastolic balloon inflation) and reduces systemic afterload
(during systolic balloon deflation). The use of positive inotropes
can also improve the hemodynamic status. In the patient with
suspected TC who is hypotensive, these same therapies can be used
if there is no SAM with LVOTO. By contrast, if there is
significant LVOTO, both IABP placement and inotropes are
relatively contraindicated because they would worsen the dynamic
gradient and thereby further jeopardize cardiac function (6).
Therefore, patients with predominant pump failure can safely
receive IABP counterpulsation and inotropes, whereas those with
significant LVOTO should instead be managed more conserva-
tively with cautious fluids (if no pulmonary edema) and beta-
blockers (to increase diastolic filling time and thus end-diastolic
volume) (7).
We congratulate the authors on their retrospectively developed
and prospectively validated risk scoring system. However, we
believe that their final sentence “the use of intra-aortic balloon
pump counterpulsation may be the preferred treatment strategy for
moderate or severe hemodynamic compromise” would be further
enhanced by the addition of the important clinical caveat “assum-
ing there is no echocardiographic evidence of LVOTO.” We
wonder whether the authors encountered cases of LVOTO in their
series, and, if so, what percentage of these patients had acute heart
